Author: da Costa, Cesar Martins; de Souza, Zenaide Silva; Real Salgues, Alessandra Corte; Harada, Guilherme; Marino Rodrigues Ayres, Pedro Paulo; Vieira Nunes, Daniela Bulhões; Katz, Artur; Munhoz, Rodrigo Ramella
Title: COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy Cord-id: netjvzxw Document date: 2020_9_9
ID: netjvzxw
Snippet: Background: Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation: A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting
Document: Background: Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation: A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient’s discharge after 81 days of hospitalization. Conclusion: A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.
Search related documents:
Co phrase search for related documents- acute kidney injury and lung cancer: 1, 2, 3, 4, 5, 6, 7
- acute kidney injury and lymph node: 1, 2
- acute respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lymph node: 1, 2
- adaptive innate and lung cancer: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
- adjuvant radiation therapy and lung cancer: 1, 2, 3
- adjuvant radiation therapy and lymph node: 1, 2
Co phrase search for related documents, hyperlinks ordered by date